Versartis’ Long-Acting Somavaratan for Growth Hormone Deficiency to be Featured in Multiple Oral and Poster Presentations at ENDO ...
36-month data in pediatric GHD, showing consistent safety and efficacy profile through 3 years of treatment Baseline characteristics of Phase 3 VELOCITY study population comparable to Phase 2 Additional results from the VITAL trial in adult GHD MENLO PARK, …